Assistant Professor, Medicine, University of California Los Angeles David Geffen SOM
Oncology
Dr. Sara A. Hurvitz, MD
|
|
Give Review
Sara Hurvitz is an expert in the field of Oncology. She studied medicine at Keck School of Medicine of USC. Keck School of Medicine of USC is ranked 31/72 in Research/PrimaryCare. She received 2 awards: "Regional Top Doctor" and "Super Doctor". Sara Hurvitz is also published. She has 44 publications published. The lastest publication: "MCT1 Modulates Cancer Cell Pyruvate Export and Growth of Tumors that Co-express MCT1 and MCT4.' She accepts Medicare.
Publications
- Statistical Controversies in Clinical Research: Statistical significance - too much of a good thing….
- MCT1 Modulates Cancer Cell Pyruvate Export and Growth of Tumors that Co-express MCT1 and MCT4.
- Triple-negative breast Cancer: advancements in characterization and treatment approach.
- Trebananib (AMG 386) plus weekly paclitaxel with or without bevacizumab as first-line therapy for HER2-negative locally recurrent or metastatic breast Cancer: A phase ...
- Symptom Burden and Quality of Life among Women with HER2(+) Metastatic Breast Cancer.
- Estrogen Receptor (ER)α-regulated Lipocalin 2 Expression in Adipose Tissue Links Obesity with Breast Cancer Progression.
- In vitro activity of the mTOR inhibitor everolimus, in a large panel of breast Cancer cell lines and analysis for predictors of response.
- Recent advances in the development of anti-HER2 antibodies and antibody-drug conjugates.
- Investigation of adverse-event-related costs for patients with metastatic breast Cancer in a real-world setting.
- Targeting PI3K/mTOR Overcomes Resistance to HER2-Targeted Therapy Independent of Feedback Activation of AKT.
- Afatinib in the treatment of breast Cancer.
- Treatment of Trastuzumab-Refractory, HER2-Positive Metastatic Breast Cancer.
- PI3K pathway inhibitors for the treatment of brain metastases with a focus on HER2+ breast Cancer.
- nab-Paclitaxel in combination with biologically targeted agents for early and metastatic breast Cancer.
- Use of the metastatic breast Cancer progression (MBC-P) questionnaire to assess the value of progression-free survival for women with metastatic breast Cancer.
- A phase 2 study of everolimus combined with trastuzumab and paclitaxel in patients with HER2-overexpressing advanced breast Cancer that progressed during prior trastuz...
- Noninfectious pneumonitis with the use of mTOR inhibitors in breast Cancer.
- Trastuzumab emtansine: the first targeted chemotherapy for treatment of breast Cancer.
- Phase II Randomized Study of Trastuzumab Emtansine Versus Trastuzumab Plus Docetaxel in Patients With Human Epidermal Growth Factor Receptor 2-Positive Metastatic Brea...
- The potential for trastuzumab emtansine in human epidermal growth factor receptor 2 positive metastatic breast Cancer: latest evidence and ongoing studies.
- Combination of Cyclophosphamide, Rituximab, and Intratumoral CpG Oligodeoxynucleotide Successfully Eradicates Established B cell Lymphoma.
- Current approaches and future directions in the treatment of HER2-positive breast Cancer.
- Analysis of Fcγ receptor IIIa and IIa polymorphisms: lack of correlation with outcome in trastuzumab-treated breast Cancer patients.
- Evolving options for the treatment of metastatic breast Cancer: Progression-free survival as an endpoint.
- Phase I study of everolimus plus weekly paclitaxel and trastuzumab in patients with metastatic breast Cancer pretreated with trastuzumab.
- A phase II trial of docetaxel with bevacizumab as first-line therapy for HER2-negative metastatic breast Cancer (TORI B01).
- Phase I study of ipilimumab, an anti-CTLA-4 monoclonal antibody, in patients with relapsed and refractory B-cell non-Hodgkin Lymphoma.
- Rational management of endocrine resistance in breast Cancer: a comprehensive review of estrogen receptor biology, treatment options, and future directions.
- Sulfhydryl-based tumor antigen-carrier protein conjugates stimulate superior antitumor immunity against B cell Lymphomas.
- Primary dural marginal zone lymphoma in a woman with inflammatory breast Cancer.
- Current status of therapeutic vaccines for non-Hodgkin's Lymphoma.
- What''s positive about ''triple-negative'' breast Cancer?
- Surgical decompression of the first part of vertebral artery for ischemic Brainstem dysfunction.
- Successful treatment with cyclophosphamide of life-threatening diffuse hemangiomatosis involving the Liver.
- Recombinant, tumour-derived idiotype vaccination for indolent B cell non-Hodgkin''s Lymphomas: a focus on FavId.
- Motesanib, or open-label bevacizumab, in combination with paclitaxel, as first-line treatment for HER2-negative locally recurrent or metastatic breast Cancer: a phase ...
- Human epidermal growth factor receptor-2-positive breast Cancer: Current management of early, advanced, and recurrent disease.
- RIBBON-2: A Randomized, Double-Blind, Placebo-Controlled, Phase III Trial Evaluating the Efficacy and Safety of Bevacizumab in Combination With Chemotherapy for Second...
- Role of age and health in treatment recommendations for older adults with breast Cancer: the perspective of oncologists and primary care providers.
- Perspectives and attitudes on the use of adjuvant chemotherapy and trastuzumab in older adults with HER-2+ breast Cancer: a survey of oncologists.
- The SystHERs registry: an observational cohort study of treatment patterns and outcomes in patients with human epidermal growth factor receptor 2-positive metastatic b...
- Cardiac safety results from a phase II, open-label, multicenter, pilot study of two docetaxel-based regimens plus bevacizumab for the adjuvant treatment of subjects wi...
- Profiling and targeting HER2-positive breast Cancer using trastuzumab emtansine.
Schools
Keck School Of Medicine Of The Univ Of Southern California
UCLA Medical Center
UC Irvine
Conditions Treated
- Acute Leukemia
- Adrenal Gland Cancer
- Anemia
- Brain and Nervous System Cancer (incl. Gliomas, Astrocytoma, Schwannoma, Medulloblastoma, Chordoma)
- View All
Doctors Specialties
- Hematology
- Medical Oncology
- Oncology
Accepted Insurances
Awards
- Regional Top Doctor
- Super Doctor
Education
-
UCLA Medical Center -
Keck School of Medicine of USC
Hospital
-
Ronald Reagan UCLA Medical Center -
Santa Monica-UCLA Medical Center and Orthopaedic Hospital
Drug Facts
| NPI NUMBER | 1972527810 | |
| NPPES Provider LastName | HURVITZ | |
| NPPES Provider FirstName | SARA | |
| NPPES Provider ZIPCode | 90095 | |
| NPPES Provider State | CA | |
| Specialty Description | Internal Medicine | |
| Total Claim Count | 523.0 | |
| Distinct Opioid Count | 0.0 | |
| Opioid Claim Count | 0.0 | |
| Percent Opioid Claims | 0.0 |
Helpful Reviews
Medicare Facts
| National Provider Identifier [NPI] | 1972527810 |
| Last Name Of The Provider | HURVITZ |
| First Name Of The Provider | SARA |
| View All |
Similar Doctors
|
Dr. Sant P. Chawla, MD
 This Doctor is OpenDoctor Recommended.
 This doctor has more publications
|
|
|
Dr. Peter D. Boasberg, MD
This Doctor is OpenDoctor Recommended.
|
|
|
Dr. Rena D. Callahan, MD
This Doctor is OpenDoctor Recommended.
|
|
|
Dr. Marilou Terpenning, MD
This Doctor is OpenDoctor Recommended.
|
|
|
Dr. Herbert A. Eradat, MD
This Doctor is OpenDoctor Recommended.
|
|
|
Dr. Lawrence Piro, MD
This Doctor is OpenDoctor Recommended.
This doctor has more publications
|
|
|
Dr. Leonard S. Goldberg, MD |
|
|
Dr. Sebastian J. Sasu, MD
This Doctor is OpenDoctor Recommended.
|
|
|
Dr. Saeed W. Sadeghi, MD
This Doctor is OpenDoctor Recommended.
|
|
|
Dr. Robert I. Lehrer, MD
This Doctor is OpenDoctor Recommended.
|
|
|
Dr. Kamalesh K. Sankhala, MD
This Doctor is OpenDoctor Recommended.
|
|
|
Dr. Francis P. Cyran, MD
This Doctor is OpenDoctor Recommended.
|
|
|
Dr. John M. Timmerman, MD
This Doctor is OpenDoctor Recommended.
This doctor has more publications
|